HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Drug Safety France Regulation

France Warns Of Serious Complications Related To OTC Ibuprofen Use

  • News

Executive Summary

French medicines regulator ANSM warns that use of certain OTC NSAIDs increases the risk of serious complications when suffering from a minor infection. The agency is advising consumers not to use iburofen or ketoprofen to treat pain or fever, and to instead opt for paracetamol. 

You may also be interested in...



EMA Committee Warns Ibuprofen Can Seriously Exacerbate Infections

EMA's Pharmacovigilance Risk Assessment Committee wants ibuprofen and ketoprofen products to carry new warnings related to the risk of exacerbating serious infections. 

‘Insufficient Evidence’ Ibuprofen Worsens COVID-19, Says UK Regulator

Review by MHRA advisory body finds no issue with ibuprofen use in COVID-19 patients and updates advice to recommend either paracetamol or ibuprofen to treat symptoms. 

France Moving Paracetamol and NSAIDs Behind Pharmacy Counter From January

Fears over patient safety will see common OTC drugs including paracetamol moved behind the counter in France from January 2020.

Table

View full table

Related Content

HBW Insight
Generics Bulletin
HBW Insight
HBW Insight
HBW Insight
HBW Insight
HBW Insight

Topics

Related Companies

Tags:
Drug Safety France Regulation
UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By